Results 141 to 150 of about 1,574,238 (214)

Opioid withdrawal syndrome‐associated cognitive impairment: A narrative review

The American Journal on Addictions, Volume 35, Issue 6, Page 661-672, November 2026.
Abstract Background and Objectives Opioid withdrawal syndrome (OWS) comprises a transient constellation of subjective symptoms and objective signs expressed by brain and other organs. Although cognitive impairment is well documented in opioid use and addiction, little is known about cognitive impairment that may specifically accompany OWS.
Faizan Khan, Nazli Tunali, R. Andrew Chambers   +2 more
wiley   +1 more source

Diagnosis and Management of Nitazene Dependence in Sydney, Australia: A Case Series

Drug and Alcohol Review, Volume 45, Issue 7, November 2026.
ABSTRACT Introduction Nitazenes are synthetic opioids with potent μ‐receptor activity. There are increasing reports of nitazene overdoses worldwide. We report on a case series of protonitazene and metonitazene dependence responding to high dose medication for the treatment of opioid dependence in both inpatient and outpatient settings.
Daniel Dutkiewicz, Hester Wilson, Peter Chisholm, Thanjira Jiranantakan, Christine Harvey, Kaniz Fatema, Mark Hardy   +6 more
wiley   +1 more source

The effect of the μ-opioid receptor antagonist naloxone on extinction of conditioned fear in the developing rat

, 2009
The effect of the μ-opioid receptor antagonist naloxone on extinction of conditioned fear in the developing ...
Jee Hyun Kim (13075509), R Richardson (13392732)   +1 more
core  

Opioid Modulation of Major Neurotransmitter Systems: Acute, Chronic, and Withdrawal Effects

European Journal of Neuroscience, Volume 64, Issue 9, November 2026.
Opioids are widely used but also frequently misused drugs that affect multiple neurotransmitter systems, including dopaminergic, glutamatergic, GABAergic, serotonergic, and cholinergic pathways. Opioid‐induced neuroadaptations depend on the duration of drug exposure, with distinct changes also emerging following drug discontinuation.
Daniela Novakova, Eliska Pritulova, Jiri Novotny   +2 more
wiley   +1 more source

In Silico to In Cerebro—Development of the Orexin Receptor Antagonist “Photorexant” for Photomodulation In Vitro and in Mouse Brains

Angewandte Chemie International Edition, Volume 65, Issue 42, 12 October 2026.
Following a structure‐based design approach, photoswitchable derivatives of the FDA‐approved drug suvorexant were designed, docked, synthesized, and characterized pharmacologically at the orexin 1 and 2 receptors (OX1R and OX2R). Optimized “photorexant” showed up to an 11‐fold difference in IC50 between photoisomers, enabled dynamic and reversible ...
Marcus Angermann, Marie H. Deventer, Vicente Ledesma‐Martin, Nuno Martinho, Alix Flake, Silvia Mori, Angel Nuñez, Jaime Pignatelli, Rita C. Guedes, Christophe P. Stove, Michael Decker   +10 more
wiley   +1 more source

Clinical Evaluation of Biased μ-Opioid Receptor Agonists: A Narrative Comparative Review from Oliceridine to Tegileridine and Mechanistic Reappraisal. [PDF]

Drug Des Devel Ther
Xu H, Wang Y, Hu N, Lei Q, Guo X, Zhong M.   +5 more
europepmc   +1 more source

Naltrexone, Naloxone, Morphine, and Fentanyl Pharmacologically Chaperone a Mutant μ-Opioid Receptor via an Endoplasmic Reticulum Exit Site-Dependent Pathway. [PDF]

Pharmacol Res Perspect
Grant SN, Mulcahy MJ, Lester HA.
europepmc   +1 more source

Structural Determinants of μ-Opioid Receptor Antagonism and Respiratory Liability in Phenylfentanyl Analogues. [PDF]

ACS Chem Neurosci
Li E, Kale BS, Silte AA, Lyu R, Upadhyay N, Neel LT, Reda A, Wang H, Dewey WL, Pagare PP, Zhang Y.   +10 more
europepmc   +1 more source

Investigation of the In Vitro and In Vivo Metabolism and μ-Opioid Receptor Affinity of the Nitazene N-Pyrrolidino Fluetonitazene. [PDF]

Drug Test Anal
Zemp S, Alluisetti G, Weinmann W, Schrag B, Sporkert F, Leclerc M, Grafinger KE.   +6 more
europepmc   +1 more source

Quantitative μ-Opioid Receptor PET with [¹⁸F]FCFN in Nonhuman Primates: Naloxone Blockade and Within-Scan Displacement. [PDF]

Pharmaceutics
Gallagher E, Downey JW, Yoo CH, Deng H, Fu JF, Qin Q, Bass I, Wey HY, Hooker JM, Sander CY, Lee SJ.   +10 more
europepmc   +1 more source